{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:43:23Z","timestamp":1760298203090},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,12,4]],"date-time":"2009-12-04T00:00:00Z","timestamp":1259884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00280-009-1181-8","type":"journal-article","created":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T11:23:53Z","timestamp":1259839433000},"page":"455-466","source":"Crossref","is-referenced-by-count":22,"title":["Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines"],"prefix":"10.1007","volume":"66","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun K.","family":"Rishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineshkumar T.","family":"Puliyappadamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Tarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Ping Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvio","family":"Lonardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Ruckdeschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Wali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"1181_CR1","unstructured":"Antman KH, Pass HI, Schiff PB (2001) Benign and malignant mesothelioma. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott-Raven, Philadelphia, pp 1943\u20131970"},{"key":"1181_CR2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","volume":"79","author":"J Peto","year":"1999","unstructured":"Peto J, Decaril A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79:666\u2013672","journal-title":"Br J Cancer"},{"key":"1181_CR3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1378\/chest.116.2.504","volume":"116","author":"DH Sterman","year":"1999","unstructured":"Sterman DH, Kaiser LR, Albelda SM (1999) Advances in the treatment of malignant pleural mesothelioma. Chest 116:504\u2013520","journal-title":"Chest"},{"key":"1181_CR4","doi-asserted-by":"crossref","first-page":"66S","DOI":"10.1378\/chest.113.1_Supplement.66S","volume":"113","author":"CW Ryan","year":"1998","unstructured":"Ryan CW, Herndon J, Vogelzang NJ (1998) A review of chemotherapy trials for malignant mesothelioma. Chest 113:66S\u201373S","journal-title":"Chest"},{"issue":"4","key":"1181_CR5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11912-005-0048-3","volume":"7","author":"RK Goudar","year":"2005","unstructured":"Goudar RK (2005) New therapeutic options for mesothelioma. Curr Oncol Rep 7(4):260\u2013265","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"1181_CR6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.hoc.2005.09.010","volume":"19","author":"LM Krug","year":"2005","unstructured":"Krug LM (2005) An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 19(6):1117\u20131136","journal-title":"Hematol Oncol Clin North Am"},{"key":"1181_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr460","volume":"5","author":"RZ Orlowski","year":"2003","unstructured":"Orlowski RZ, Dees EC (2003) Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 5:1\u20137","journal-title":"Breast Cancer Res"},{"issue":"5","key":"1181_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/107327480301000502","volume":"10","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Hideshima T, Anderson KC (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10(5):361\u2013369 Review","journal-title":"Cancer Control"},{"key":"1181_CR9","first-page":"828","volume":"5","author":"QP Dou","year":"2002","unstructured":"Dou QP, Goldfarb RH (2002) Bortezomib\/P341 (millennium pharmaceuticals) (invited review). IDrugs 5:828\u2013834","journal-title":"IDrugs"},{"key":"1181_CR10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8:508\u2013513","journal-title":"Oncologist"},{"key":"1181_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The proteosome: a suitable antineoplastic target. Nat Rev Cancer 4:349\u2013360","journal-title":"Nat Rev Cancer"},{"key":"1181_CR12","doi-asserted-by":"crossref","first-page":"33422","DOI":"10.1074\/jbc.M303173200","volume":"278","author":"AK Rishi","year":"2003","unstructured":"Rishi AK, Zhang L, Boyanapalli M, Wali A, Mohammad RM, Yu Y, Fontana JA, Hatfield JS, Dawson MI, Majumdar APN, Reichert U (2003) Identification and characterization of a Cell-Cycle and Apoptosis Regulatory Protein (CARP)-1 as a novel mediator of apoptosis signaling by Retinoid CD437. J Biol Chem 278:33422\u201333435","journal-title":"J Biol Chem"},{"key":"1181_CR13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.neuron.2004.12.050","volume":"45","author":"Z Shao","year":"2005","unstructured":"Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire N, Thill G, Levesque M, Sah D, McCoy JM, Murray B, Jung V, Pepinsky RB, Mi S (2005) TAJ\/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 45:353\u2013359","journal-title":"Neuron"},{"issue":"2","key":"1181_CR14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/35055027","volume":"3","author":"P Liston","year":"2001","unstructured":"Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, McBurney MW, Korneluk RG (2001) Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 3(2):128\u2013133","journal-title":"Nat Cell Biol"},{"issue":"15","key":"1181_CR15","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","volume":"353","author":"HI Pass","year":"2005","unstructured":"Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353(15):1564\u20131573","journal-title":"N Engl J Med"},{"key":"1181_CR16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/0-387-29362-0_23","volume-title":"Bioinformatics and computational biology solutions using R and bioconductor","author":"GK Smyth","year":"2005","unstructured":"Smyth GK, Limma L (2005) Liner models for microarray data. In: Gentleman R, Carey V, Duoit S, Irizarry R, Huber W (eds) Bioinformatics and computational biology solutions using R and bioconductor. Springer, New York, pp 397\u2013420"},{"key":"1181_CR17","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1371\/journal.pcbi.0030116","volume":"3","author":"AL Tarca","year":"2007","unstructured":"Tarca AL, Carey VJ, Chen XW, Romero R, Dr\u00e3ghici S (2007) Machine learning and its applications to biology. PLoS Comput Biol 3:e116","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"1181_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2004.10.011","volume":"48","author":"A Wali","year":"2005","unstructured":"Wali A, Morin PJ, Hough CD, Lonardo F, Seya T, Carbone M, Pass HI (2005) Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer 48(1):19\u201329","journal-title":"Lung Cancer"},{"issue":"19","key":"1181_CR19","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-07-0536","volume":"13","author":"A Sartore-Bianchi","year":"2007","unstructured":"Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L (2007) Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13(19):5942\u20135951","journal-title":"Clin Cancer Res"},{"key":"1181_CR20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/371346a0","volume":"371","author":"YA Lazebnik","year":"1994","unstructured":"Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371:346\u2013347","journal-title":"Nature"},{"key":"1181_CR21","doi-asserted-by":"crossref","first-page":"13188","DOI":"10.1074\/jbc.M512279200","volume":"281","author":"AK Rishi","year":"2006","unstructured":"Rishi AK, Zhang L, Yu Y, Jiang Y, Nautiyal J, Wali A, Fontana JA, Levi E, Majumdar APN (2006) Cell cycle and apoptosis regulatory protein (CARP)-1 is involved in apoptosis signaling by epidermal growth factor receptor. J Biol Chem 281:13188\u201313198","journal-title":"J Biol Chem"},{"key":"1181_CR22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.molcel.2008.08.001","volume":"31","author":"JH Kim","year":"2008","unstructured":"Kim JH, Yang CK, Heo K, Roeder RG, An W, Stallcup MR (2008) CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes. Mol Cell 31:510\u2013519","journal-title":"Mol Cell"},{"issue":"31","key":"1181_CR23","doi-asserted-by":"crossref","first-page":"20629","DOI":"10.1074\/jbc.M109.014332","volume":"284","author":"CY Ou","year":"2009","unstructured":"Ou CY, Kim JH, Yang CK, Stallcup MR (2009) Requirement of cell cycle and apoptosis regulator 1 for target gene activation by Wnt and {beta}-catenin and for anchorage-independent growth of human colon carcinoma cells. J Biol Chem 284(31):20629\u201320637","journal-title":"J Biol Chem"},{"issue":"3","key":"1181_CR24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1593\/tlo.08133","volume":"1","author":"BZ Yuan","year":"2008","unstructured":"Yuan BZ, Chapman JA, Reynolds SH (2008) Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Transl Oncol 1(3):129\u2013140","journal-title":"Transl Oncol"},{"issue":"4","key":"1181_CR25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/path.2120","volume":"211","author":"GJ Gordon","year":"2007","unstructured":"Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ, Bueno R (2007) Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 211(4):439\u2013446","journal-title":"J Pathol"},{"issue":"4","key":"1181_CR26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00280-007-0500-1","volume":"61","author":"GJ Gordon","year":"2008","unstructured":"Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R (2008) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61(4):549\u2013558","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1181_CR27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/sj.onc.1209809","volume":"26","author":"AC Borczuk","year":"2007","unstructured":"Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN, Powell CA (2007) Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 26(4):610\u2013617","journal-title":"Oncogene"},{"key":"1181_CR28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","volume":"27","author":"DA Fennell","year":"2008","unstructured":"Fennell DA, Chacko A, Mutti L (2008) BCL-1 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27:1189\u20131197","journal-title":"Oncogene"},{"key":"1181_CR29","first-page":"139","volume":"20","author":"S Morohashi","year":"2007","unstructured":"Morohashi S, Kusumi T, Sato F, Odagiri H, Chiba H, Yoshihara S, Hakamada K, Sasaki M, Kijima H (2007) Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 20:139\u2013143","journal-title":"Int J Mol Med"},{"key":"1181_CR30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/35067088","volume":"2","author":"S Tsukita","year":"2001","unstructured":"Tsukita S, Furuse M, Itoh M (2001) Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2:285\u2013293","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1181-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1181-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:07:03Z","timestamp":1559038023000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1181-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1181-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,4]]}}}